The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.
 
Nan Chen
Employment - GlaxoSmithKline (I)
Consulting or Advisory Role - AstraZeneca; GE Healthcare; Gilead Sciences
 
Elena Michaels
No Relationships to Disclose
 
Poornima Saha
No Relationships to Disclose
 
Murtuza M. Rampurwala
Stock and Other Ownership Interests - GlaxoSmithKline
Honoraria - Medscape
Consulting or Advisory Role - Celgene; HERON; Puma Biotechnology
Travel, Accommodations, Expenses - Daiichi Sankyo Pharmaceutical; DAVA Oncology; Merck
 
Olwen Mary Hahn
Employment - Solaris Health (I)
Leadership - Via Oncology
Stock and Other Ownership Interests - novavax; Teleflex Medical; Teleflex Medical
Honoraria - Cardinal Health (I)
Consulting or Advisory Role - HMP; Pfizer
Travel, Accommodations, Expenses - Cardinal Health (I)
 
Frederick Matthew Howard
No Relationships to Disclose
 
Gini F. Fleming
Honoraria - Physicans' Education Resource
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Celldex (Inst); Compugen (Inst); Compugen (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); K-Group Beta (Inst); Merck (Inst); Molecular Templates (Inst); P{fizer (Inst); Pfizer (Inst); Plexxikon (Inst); Roche (Inst); Sermonix Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst)
Other Relationship - AstraZeneca (Inst); Caris Life Sciences (Inst); DSI (Inst); Eisai (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie
 
Theodore Karrison
No Relationships to Disclose
 
Suzanne D. Conzen
Patents, Royalties, Other Intellectual Property - A GR antagonist methods patent owned by the University of Chicago that I am a co-Inventor on is licensed to Corcept Therapeutics
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; BeyondSpring Pharmaceuticals; Cardinal Health; Fujifilm; GE Healthcare; Gilead Sciences; Infinity Pharmaceuticals; ITeos Therapeutics; Merck; OBI Pharma; OncoSec; Sanofi; Seagen
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sun Pharma (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics